OBI Pharma Inc. announces the change of Chief Operating Officer

Clarification on the news article by Commercial Times
January 21, 2017
OBI-822 was approved to enter a Phase III clinical trial by the China Food and Drug Administration (CFDA)
January 25, 2017
  1. Type of personnel changed (please enter: spokesperson, acting spokesperson, important personnel(CEO, COO, CMO, CSO, etc.),financial officer, accounting officer, research and development officer, or internal audit officer): Chief Operating Officer
  2. Date of occurrence of the change: January 23, 2017
  3. Name, title, and resume of the replaced person: Joanna Meng, Chief Operating Officer
  4. Name, title, and resume of the replacement: Max Chan, Chief Operating Officer. Mr. Chan had previously served as the Chief Financial Officer for JHL Biotech (TPEx: 6540), TaiGen Biotech (TPEx: 4157), Himax Technologies (NASDAQ: HIMX), and manager for Intel Capital.
  5. Type of the change (please enter: “resignation”, “position adjustment”, “dismissal”, “retirement”, “death” or “new replacement” ): Retirement
  6. Reason for the change: Retirement
  7. Effective date: January 23, 2017
  8. Contact telephone number of the replacement: (02)2786-6589
  9. Any other matters that need to be specified: None.